Authored by Majeed, N. Kalyanam, PhD, president, research and development, and other members of the Sami-Sabinsa Group’s technical staff, the book details the transformation of curcumin into its metabolites inside the body, and the significance of major metabolites.
Photo © Shutterstock.com/ COLOA Studio
Muhammed Majeed, PhD, founder, chairman, and managing director of Sabinsa (East Windsor, NJ) has published a new book called “Reductive Metabolites of Curcuminoids.” Authored by Majeed, N. Kalyanam, PhD, president, research and development, and other members of the Sami-Sabinsa Group’s technical staff, the book details the transformation of curcumin into its metabolites inside the body, and the significance of major metabolites.
“The central theme of the book is to emphasize that the effects of curcumin observed in animal models and in human trials are the aggregate benefits of curcumin and the reductive metabolites of curcuminoids,” explained Majeed, in a press release. The book compiles the pharmacological activities of four reduced curcuminoids, reviews the scientific evidence on the effects of microbiota on what has been called “poor bioavailability,” and discusses the role of microbiota in transforming curcumin into its major pharmacologically potent reductive metabolite, Tetrahydrocurcumin.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.